

From: Do, Yu
To: Joan.robertson@grifols.com
Subject: Pediatric Study: Original BLA, BL 125640/0, Fibrin Sealant (Human), Instituto Grifols, S.A.
Date: Thursday, March 16, 2017 2:00:00 PM
Attachments: [image013.png](#)
Importance: High

Dear Ms. Robertson:

This is our current stance on your pediatric study under review with respect to BL 125640/0:


The deferred pediatric study under consideration would likely be a single study, provided that all three indications are sufficiently evaluated in the study. The protocol must ensure stratification based on the type of surgery, specifying a minimum required number for each procedure (sample size) to allow the Agency an assessment of the safety and hemostatic efficacy for each type of surgery.

The sponsor may submit the study under one of the existing INDs; the choice would be for the IND that has the most prevalent pediatric surgical indication. The clinical reviewer(s) will provide additional comments upon reviewing the protocol.

Please let me know if you have any additional questions. Thanks.

Sincerely,

Yu Do, M.S.
Regulatory Project Manager
Office of Tissues and Advanced Therapies
Center for Biologics Evaluation and Research
Office of Medical Products and Tobacco
Food and Drug Administration
(240) 402-8343
Yu.Do@fda.hhs.gov



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."